Mezzasalma Marco Andre, Mathias Kátia de Vasconcellos, Nascimento Isabella, Valença Alexandre M, Nardi Antonio E
Panic and Respiration Laboratory, Psychiatric Institute, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Arq Neuropsiquiatr. 2011 Apr;69(2A):196-201. doi: 10.1590/s0004-282x2011000200011.
The purpose of this study was to evaluate the efficacy and effectiveness of imipramine on the treatment of comorbid chronic dizziness and panic disorder.
Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and were treated with a 3-months course of imipramine. Anxiety levels were measured with the Hamilton Anxiety Scale (HAM-A), dizziness levels were evaluated using the Dizziness Handicap Inventory (DHI), and panic severity and treatment outcome were assessed with the Clinical Global Impression Scale (CGI).
At the baseline 33.3% (n=3) had a bilateral peripheral deficit vestibulopathy, the mean scores for HAM-A were 27.2±10.4, for DHI were 51.7±22.7, and for CGI-S were 4.8±0.9. All patients had a significant reduction in their HAM-A (11.1±5.5, p=0.008), DHI (11.5±8.1, p=0.008) and CGI-I (1.8±0.7, p=0.011) levels after 3-months imipramine treatment (mean=72.2±23.2 mg/day).
This study found a decrease in anxiety levels and in the impact of dizziness in the patients' quality of life after a 3-months treatment course with imipramine.
本研究旨在评估丙咪嗪治疗慢性头晕合并惊恐障碍的疗效和有效性。
9例伴有慢性头晕的惊恐障碍和广场恐惧症患者接受了耳神经学筛查,并接受了为期3个月的丙咪嗪治疗。使用汉密尔顿焦虑量表(HAM-A)测量焦虑水平,使用头晕残障量表(DHI)评估头晕程度,并使用临床总体印象量表(CGI)评估惊恐严重程度和治疗结果。
基线时,33.3%(n = 3)的患者存在双侧外周前庭功能障碍,HAM-A的平均评分为27.2±10.4,DHI的平均评分为51.7±22.7,CGI-S的平均评分为4.8±0.9。在接受3个月丙咪嗪治疗(平均剂量=72.2±23.2毫克/天)后,所有患者的HAM-A(11.1±5.5,p = 0.008)、DHI(11.5±8.1,p = 0.008)和CGI-I(1.8±0.7,p = 0.011)水平均显著降低。
本研究发现,在接受为期3个月的丙咪嗪治疗后,患者的焦虑水平降低,头晕对生活质量的影响也有所减轻。